Background: Primary cutaneous T-cell lymphomas (CTCLs) are rare lymphoproliferative malignancies characterized by significant morbidity and mortality in advanced disease stages. As curative approaches apart from allogeneic stem cell transplantation are lacking, establishing new treatment options, especially combination therapies, is crucial. Methods: This retrospective study included 11 patients with SS or MF receiving therapy with mogamulizumab in combination with ECP from four European expert centers. The response rates in the skin and blood as well as treatment use and adverse events (AE) were described. Results: 8/11 patients (73%) showed an overall response (OR) in the skin. The mean mSWAT decreased from 98.2 ± 40.8 to 34.6 ± 23.8. The overall response rate (ORR) in the blood was 64% with two complete responses. During combination therapy, the mean number of Sézary cells decreased from 3365.3 × 106/L before treatment to 1268.6 × 106/L. The mean minimum known period without progress was 7.2 months in the skin and 7.6 months in the blood. The most common AEs were mogamulizumab-associated rash (MAR) (45.5%), anemia (27.3%), lymphocytopenia (27.8%), and infusion related reaction (16.7%). No AE led to treatment discontinuation. Conclusions: Our study presents the combination of mogamulizumab and ECP as an effective therapy in the blood and skin in CTCL with good tolerability, similar to mogamulizumab monotherapy.
背景：原发性皮肤T细胞淋巴瘤（CTCL）是一种罕见的淋巴增殖性恶性肿瘤，在疾病晚期阶段具有显著的发病率和死亡率。由于除异基因干细胞移植外缺乏根治性手段，建立新的治疗方案，尤其是联合疗法，至关重要。方法：这项回顾性研究纳入了来自四个欧洲专家中心的11例接受莫格利珠单抗联合体外光分离置换疗法（ECP）治疗的Sézary综合征（SS）或蕈样肉芽肿（MF）患者。描述了皮肤和血液中的缓解率，以及治疗使用情况和不良事件（AE）。结果：11例患者中有8例（73%）在皮肤方面显示出总体缓解（OR）。平均改良版严重程度加权评估工具（mSWAT）评分从98.2 ± 40.8下降至34.6 ± 23.8。血液总体缓解率（ORR）为64%，其中两例达到完全缓解。联合治疗期间，Sézary细胞平均计数从治疗前的3365.3 × 10⁶/L下降至1268.6 × 10⁶/L。皮肤和血液中已知的无进展最短平均时间分别为7.2个月和7.6个月。最常见的不良事件包括莫格利珠单抗相关皮疹（MAR）（45.5%）、贫血（27.3%）、淋巴细胞减少症（27.8%）和输注相关反应（16.7%）。无不良事件导致治疗中断。结论：我们的研究表明，莫格利珠单抗联合ECP治疗CTCL在皮肤和血液方面均有效，且耐受性良好，与莫格利珠单抗单药治疗相似。
肿瘤(癌症)患者之家